Breast Cancer

Steep Decline in Chemotherapy Use for Early-Stage Breast Cancer

The use of chemotherapy to treat women with early-stage breast cancer “declined markedly over time,” according to analysis of data from 2,926 women between the ages of 20 and 79. The trends...

Hematologic Malignancies

Pomalidomide and Low-Dose Dexamethasone in Patients With Multiple Myeloma and Renal Impairment

In a European phase II trial reported in the Journal of Clinical Oncology, Dimopoulos et al found that pomalidomide plus low-dose dexamethasone produced responses in patients with relapsed or...

Issues in Oncology

Up-to-Date Labels for Older Drugs Essential for Appropriate Use

Oncology drug labels, especially those that have been on the market for more than 15 years, may not always be up-to-date. Critical data about safety, efficacy, or prescribing information may...


More Top Stories

Issues in Oncology

Aaron Goodman, MD, on Immune Checkpoint Blockade: Clinical Implications

Photos From the 2018 Gastrointestinal Cancers Symposium, San Francisco

The 2018 Gastrointestinal Cancers Symposium was held recently in San Francisco.  Watch for coverage of these sessions and more in upcoming issues of The ASCO Post or on The 2018 Gastrointestinal Cancers Symposium was supported by ASCO, the American Society of Radiation...


FDA Accepts NDA, Grants Priority Review for Ivosidenib in Relapsed or Refractory IDH1-Mutated AML

On February 15, the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for ivosidenib (AG-120) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation. The NDA was granted Priority Review...

Issues in Oncology

Mary L. Disis, MD, on Basics of Immunology: An Overview

CNS Cancers

Addition of EGFR-Targeting Vaccine to Temozolomide in EGFRvIII-Expressing Glioblastoma

The phase III ACT IV study has shown no survival benefit of adding rindopepimut, a vaccine targeting the epidermal growth factor receptor (EGFR) deletion mutation EGFRvIII, to temozolomide in patients with newly diagnosed EGFRvIII-positive glioblastoma. These findings were reported in The Lancet...

ASCO Offers Oncology Perspective on 2018 Federal Agency Activities and Rulemaking

  AS 2017 came to a close, ASCO offered the oncology community’s perspective to federal agencies—including the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA)—in response to open comment periods before rules and plans for 2018 and 2019 programs...

Long-Term Outcomes With PD-L1 Inhibition in Metastatic Urothelial Cancer

As reported by Petrylak et al in JAMA Oncology, long-term follow-up of patients in a phase I study expansion cohort indicated enduring clinical benefit and maintained tolerability of atezolizumab (Tecentriq) in patients with metastatic urothelial carcinoma.  Study Details The study involved...


Flora E. van Leeuwen, PhD, on Hodgkin Lymphoma Treatment: Toxicities in Female Survivors

Breast Cancer

CDK 4/6 Inhibitors May Be Effective but More Toxic in Older Women

OLDER WOMEN with breast cancer derive benefit from treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors as part of initial endocrine-based therapy for hormone receptor–positive, HER2-negative, metastatic breast cancer, according to a retrospective pooled subgroup analysis of women aged 70 or ...


Chromatin Organization Marker and Cancer-Specific Survival

In a study reported in The Lancet Oncology, Kleppe et al found that a novel marker for chromatin organization in tumor cell nuclei was associated with outcome in a variety of cancer types. Study Details In the study, machine learning algorithms analyzed chromatin organization in 461,000 images of ...